On Friday, Glu Mobile (SWX:GLUU) s shares inclined 0.60% to $6.71.
Glu Mobile(GLUU) declared the availability of Terminator Genisys: Revolution on the App Store and Google Play. In partnership with Skydance Productions, Glu has developed the official mobile game in conjunction with the new Terminator Genisys film planned for U.S. theatrical release from Paramount Pictures on July 1, 2015.
Glu Mobile Inc. develops, publishes, and markets a portfolio of games for the smartphones and tablet devices users. The company offers free-to-play action, casual, racing, and sports genre mobile games.
Hanesbrands Inc. (NYSE:HBI)’s shares gained 0.90% to $32.35.
Hanesbrands Inc. (HBI) declared that it has awarded Wake Forest Baptist Medical Center and its medical professionals with the company’s first Hanes for Good Champion Award for outstanding commitment to community service.
Hanes has partnered with the medical center since 2012 to conduct eight volunteer surgical missions to the Dominican Republic where Hanes has more than 8,000 employees. The medical center’s otolaryngology medical teams have performed more than 500 life-altering ear, nose and throat surgeries and have treated more than 4,000 patients.
Hanes, a leader in corporate social responsibility in the apparel industry, honored Wake Forest Baptist, its medial teams and two Hanes employee volunteers at the company’s annual leadership meeting being held in Winston-Salem and attended by more than 600 Hanes professionals.
Hanesbrands Inc., a consumer goods company, designs, manufactures, sources, and sells a range of basic apparels for men, women, and children in the United States. The company operates through four segments: Innerwear, Activewear, Direct to Consumer, and International. It sells bras, panties, shapewears, hosiery, men’s underwear, children’s underwear, and socks; and other activewear, such as T-shirts, fleece, sport shirts, performance T-shirts and shorts, sports bras, and thermals, in addition to licensed logo apparel in collegiate bookstores and other channels.
At the end of Friday’s trade, CME Group Inc (NASDAQ:CME)‘s shares surged 1.81% to $95.95.
CME Group Inc (CME) declared that May 2015 volume averaged 14.1 million contracts per day, up 8 percent from May 2014. Total volume for May 2015 was more than 281 million contracts, of which 88 percent was traded electronically. Options volume in May averaged 2.6 million contracts per day, up 13 percent as compared to May 2014, with electronic options growing 33 percent over the same period.
CME Group interest rate volume averaged 7.8 million contracts per day in May 2015, up 3 percent contrast with May 2014. Treasury average daily volume rose 12 percent, with Treasury futures volume of 4.0 million contracts per day, up 11 percent from the same period a year ago, and Treasury options volume of 712,000 contracts per day, up 22 percent. Eurodollar futures volume averaged 2.3 million contracts per day, down 10 percent contrast with May 2014, and Eurodollar options volume averaged 738,000 contracts per day, down 8 percent.
CME Group Inc., through its auxiliaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products for trading and/or clearing across various asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals. The products comprise exchange-traded; and privately negotiated futures and options contracts and swaps.
Horizon Pharma PLC (NASDAQ:HZNP), ended its Friday’s trading session with 3.07% gain, and closed at $32.27.
Horizon Pharma PLC (HZNP) a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, recently declared it has initiated the Phase 3 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich’s Ataxia study (“STEADFAST”) of ACTIMMUNE (interferon gamma-1b) for the treatment of people with Friedreich’s Ataxia (FA), a degenerative neuro-muscular disorder.
In addition to safety and efficacy, the STEADFAST trial will evaluate the pharmacokinetic characteristics of ACTIMMUNE in people with FA.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
